Day: December 22, 2020

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) — Titanium Corporation Inc. (the “Company” or “Titanium”) (TSX-V: TIC) is pleased to announce that the Company and Canadian Natural Resources Limited (“Canadian Natural”) have signed a 2020 Project Coordination Agreement (“PCA”) which governs the 2020 engineering phase of the CVW™ Horizon Project (the “2020 Program”).The PCA, effective January 1, 2020, sets out the rights and responsibilities under which the parties have been operating during the year with respect to the 2020 Program. Under the PCA, the 2020 Program includes validation of the previously completed front end engineering design study, optimization of the overall plant design and the updating of the capital cost estimate for the concentrator plant, tailings thickener and associated utilities.The...

San Francisco, CA, Dec. 22, 2020 (GLOBE NEWSWIRE) — 7GC & Co. Holdings Inc. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading tomorrow, Wednesday, December 23, 2020, under the ticker symbol “VIIAU.” Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade.  Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “VII” and “VIIAW,” respectively.The...

Met primary endpoint with robust statistical significanceShowed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significanceShowed statistically significant onset of action as early as week 2Had a good safety and tolerability profile throughout the studyTopline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescentsROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).At a daily dose of up to 600mg,...

MADISON, Wis., Dec. 22, 2020 (GLOBE NEWSWIRE) — Sonic Foundry, Inc. (OTC Pink Sheets: SOFO), the trusted leader for video creation and management solutions, as well as virtual and hybrid events, today announced consolidated financial results for its fiscal 2020 fourth quarter and fiscal year ended September 30, 2020.Fiscal 2020 Fourth Quarter HighlightsBillings of $11 million in the fourth quarter of 2020, a $1.2 million increase over the same quarter last yearTotal revenues of $10.2 million compared to $9.2 million in the fourth quarter of 2019, a 10 percent increaseGross margin was $7.3 million, or 72 percent in the fourth quarter of 2020 compared to $6.5 million, or 70 percent in the fourth quarter of 2019Net income attributable to common stockholders of $439,000, or $0.06 per share, compared to a net loss of $(179,000), or $(0.03)...

Improves liquidity and operating flexibilitySignificantly reduces borrowing costsSupports ongoing transformation to profitable growth platformHOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 million credit facility (the “Refinancing”). Proceeds from the new facility will be used to retire existing debt and pay related fees and expenses. The Refinancing significantly reduces borrowing costs while increasing operating flexibility through less restrictive financial covenants and access to higher levels of revolver borrowings.   “We are pleased with the successful execution of this refinancing and the substantial improvement in terms from our existing facility,” commented Michael Rossi, Chief Financial...

Guernsey, Channel Islands, Dec. 22, 2020 (GLOBE NEWSWIRE) — AP Alternative Assets, L.P. (“AAA”; Euronext Amsterdam: AAA) announces that Euronext Amsterdam N.V. has consented to the delisting of AAA’s units from Euronext Amsterdam, which shall occur on December 28, 2020. Following the delisting AAA shall be liquidated.Reference is made to the December 4 and 9, 2020 announcements for more information on the voluntary liquidation of AAA and the delisting of the units from Euronext Amsterdam.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About...

BEDMINSTER, NJ, Dec. 22, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) (the “Company”), the holding company for Peapack-Gladstone Bank, today announced the completion of its private placement of $100.0 million in fixed-to-floating rate subordinated notes due 2030 (the “Notes”). The Notes are intended to qualify as Tier 2 capital for regulatory purposes.  The Notes will initially bear interest at a fixed annual rate of 3.50% for the first five years and will reset quarterly thereafter to the then current three-month SOFR rate plus 326 basis points.The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the potential redemption of existing subordinated debentures, acquisitions of wealth management firms...

FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it intends to offer and sell shares of its common stock and common stock equivalents in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Concurrently with the completion of the public offering, the Company expects to sell to certain investors in a private placement, shares of common stock and convertible preferred stock at a price equal to the public offering price.Oppenheimer & Co. Inc. is acting as the...

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”, or the “Corporation”) (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.During business proceedings at the Meeting, shareholders elected six (6) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 9, 2020 (the “Information Circular”). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.A webcast archive of the executive presentation portion of the Meeting will be available HERE no later than 7:00...

New York, NY, Dec. 22, 2020 (GLOBE NEWSWIRE) — MedTech Acquisition Corporation (the “Company”) announced today that it closed its initial public offering of 25,000,000 units, which included 3,000,000 units pursuant to the partial exercise of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $250,000,000.The Company’s units are listed on the Nasdaq Capital Market (“Nasdaq”) and commenced trading under the ticker symbol “MTACU” on December 18, 2020. Each unit consists of one share of the Company’s Class A common stock and one-third of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade.  Once the securities comprising the...